Since 2008, GemVax & KAEL has operated as a cutting-edge research and development company developing proprietary peptide drug, GV1001, for treatment against various cancers and neurodegenerative disease including Alzheimer's disease and Progressive Supranuclear palsy.
The fundamental driving purpose of our innovative pharmaceutical research is to facilitate significant improvements to human life through the introduction of advanced medical technology and innovation rooted in advanced scientific measures.
At GemVax, we take pride in our proactive approach to medical research, and our progressive peptide-drug focused advancements have played a crucial role in the incessant global battle against incurable disease.
Company Details
- Employees
- 37
- Founded
- -
- Address
- 성남시, 경기도
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- kael.co.kr
- Keywords
- drug development, biopharmaceutical, peptide drug, hTERT, Alzheimer's disease, PSP, Cancer, BPH.
- HQ
- 성남시, 경기도
Gemvax & Kael Questions
Gemvax & Kael's website is kael.co.kr
Gemvax & Kael's LinkedIn profile is https://kr.linkedin.com/company/gemvax
Gemvax & Kael has
37 employees.
View email and phone details for 37
employees at Gemvax & Kael.
Gemvax & Kael's industry is
Biotechnology Research
Gemvax & Kael's top competitors are
Teloid, Inc.,
Mycropore Corporation Ltd,
Curepsp,
Neurocrine Biosciences,
Jpe沅亨,
Diamir Biosciences,
Gemvax As,
Kbi한국의생명연구원,
Takeda,
Shanghai Minghui Pharmaceutical.
Gemvax & Kael's categories are Biotechnology Research
Gemvax & Kael's founding year is 1998
